Fig. 5: Representative cases showing the correlation between [68Ga]Ga-PSMA-11 uptake and short-term response to ADT + ARPIs.
![Fig. 5: Representative cases showing the correlation between [68Ga]Ga-PSMA-11 uptake and short-term response to ADT + ARPIs.](http://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs43856-026-01444-6/MediaObjects/43856_2026_1444_Fig5_HTML.png?as=webp)
A Representative patient #1: A 78-year-old male with newly diagnosed prostate cancer underwent baseline PET/MR imaging in June 2023. The primary lesion exhibited high [68Ga]Ga-PSMA-11 uptake (SUVmax = 48.82, miPSMA = 3), with a longest diameter of ~ 41.1 mm on axial pelvic MR. After 134 days of androgen deprivation therapy (Leuprorelin plus Rezvilutamide), follow-up pelvic MR in October 2023 demonstrated significant treatment response (longest diameter ~ 12.2 mm). B Representative patient #2: A 69-year-old male with newly diagnosed prostate cancer underwent baseline PET/MR imaging in September 2024. The primary lesion exhibited low [68Ga]Ga-PSMA-11 uptake (SUVmax = 6.71, miPSMA = 1), with a baseline diameter of ~ 27.6 mm on axial pelvic MR. After 138 days of androgen deprivation therapy (Triptorelin plus Rezvilutamide), follow-up pelvic MR in January 2025 showed limited treatment response (longest diameter ~ 23.4 mm).
